636 related articles for article (PubMed ID: 33660514)
1. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
Xu L; Long Y; Tang X; Zhang N
Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
5. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy.
Shah P; Garris R; Abboud R; Vasudev R; Patel H; Doshi R; Shamoon F; Bikkina M
Am J Cardiol; 2019 Sep; 124(5):789-794. PubMed ID: 31307662
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
[TBL] [Abstract][Full Text] [Related]
11. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
12. Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis.
Alizadehasl A; Ghadimi N; Kaveh S; Maleki M; Ghavamzadeh A; Noohi F; Hosseinifard H
Int J Clin Pharm; 2021 Feb; 43(1):25-34. PubMed ID: 32910372
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis to Prevent Cardiotoxicity in Patients Receiving Anthracycline for Breast Cancer: A Combined Bayesian and Frequentist Network Meta-Analysis of Randomised Controlled Trials.
Jeyaprakash P; Sangha S; Low G; Yu C; Pathan F; Negishi K
Heart Lung Circ; 2024 May; 33(5):710-720. PubMed ID: 38184425
[TBL] [Abstract][Full Text] [Related]
14. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Oikonomou EK; Kokkinidis DG; Kampaktsis PN; Amir EA; Marwick TH; Gupta D; Thavendiranathan P
JAMA Cardiol; 2019 Oct; 4(10):1007-1018. PubMed ID: 31433450
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular magnetic resonance parametric techniques to characterize myocardial effects of anthracycline therapy in adults with normal left ventricular ejection fraction: a systematic review and meta-analysis.
Musella F; Librera M; Sibilio G; Boccalatte M; Tagliamonte G; Cavaglià E; Ferrara I; Puglia M; Dell'Aversana S; Ducci CB; Dellegrottaglie S; Savarese G; Scatteia A
Curr Probl Cardiol; 2024 Jul; 49(7):102609. PubMed ID: 38697332
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines.
Mousavi N; Tan TC; Ali M; Halpern EF; Wang L; Scherrer-Crosbie M
Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):977-84. PubMed ID: 25925220
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel microRNA profile in pediatric patients with cancer treated with anthracycline chemotherapy.
Oatmen KE; Toro-Salazar OH; Hauser K; Zellars KN; Mason KC; Hor K; Gillan E; Zeiss CJ; Gatti DM; Spinale FG
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1443-H1452. PubMed ID: 30141982
[TBL] [Abstract][Full Text] [Related]
20. [Radionuclide Methods in the Assessment of Anthracycline-Induced Cardiotoxicity].
Chernov VI; Kravchuk TL; Zelchan RV; Goldberg VE
Kardiologiia; 2015; 55(7):57-62. PubMed ID: 26688927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
